SCOPUS 정보 검색 플랫폼

Nature Biotechnology

Volumn 20, Issue 8, 2002, Pages 780-784

Orphan products - Pain relief for clinical development headaches

(1) Milne, Christopher Paul a

a TUFTS UNIVERSITY SCHOOL OF MEDICINE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL LABORATORIES; DRUG PRODUCTS;

HEADACHES;

BIOTECHNOLOGY;

ORPHAN DRUG;

BIOTECHNOLOGY; COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; ARTICLE; CLINICAL TRIAL; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; DRUG LEGISLATION; DRUG MANUFACTURE; ECONOMICS; LEGAL ASPECT; RISK; TIME;

BIOTECHNOLOGY; CLINICAL TRIALS; COMMERCE; COST-BENEFIT ANALYSIS; LEGISLATION, DRUG; ORPHAN DRUG PRODUCTION; RISK; TIME FACTORS;

EID: 0036022514 PISSN: 10870156 EISSN: None Source Type: Journal
DOI: 10.1038/nbt0802-780 Document Type: Review

Times cited : (21)

References (29)

1
- 2142796255
- April 26
- (2002)

2
- 84885489701
- Biotech products proliferate, but total development times lengthen
- (2001) Tufts Center for the Study of Drug Development Impact Report , vol.3 , Issue.6
- Kaitin, K.I.¹

3
- 0035070583
- Growing pains for biopharmaceuticals
- (2001) Nat. Biotechnol. , vol.19 , pp. 307-311
- Ashton, G.¹

4
- 2142736576
- Pharmaprojects. Update Analysis
- May
- (2002) Pharmaprojects Monthly Newsletter , pp. 1-11

5
- 2142683418
- The future at FDA
- January
- (2000) Regulatory Affairs Focus , pp. 18-20

6
- 0028895424
- Research and development costs for new drugs by therapeutic category: A study of the US pharmaceutical industry
- (1995) PharmacoEconomics , vol.7 , pp. 152-169
- DiMasi, J.¹

7
- 0000128581
- Fighting the clock
- January 28
- (2002) C&EN , pp. 27-34
- Watkins, K.¹

8
- 0003372442
- Pipeline or flatline?
- (2002) Biocentury: The Bernstein Report on Business , vol.10 , Issue.11
- Usdin, S.¹

9
- 0034167166
- Understanding clinical trials
- (2000) Scientific American , vol.282 , pp. 69-75
- Zivin, J.¹

10
- 2142677208
- Is the end of trial-and-error medicine in sight?
- April
- (2002) R&D Directions , pp. 38-43
- Engel, S.¹

11
- 0035204617
- Realism in drug discovery - Could Cassandra be right?
- (2001) Nat. Biotechnol. , vol.19 , pp. 1099-1100
- Horrobin, D.¹

12
- 0026439799
- Implementation of the orphan drug act: 1983-1991
- (1992) Food & Drug Law J. , vol.47 , pp. 363-403
- Shulman, S.¹

13
- 0035013106
- Clinical development of therapeutic medicines: A biopharmaceutical versus pharmaceutical product comparison
- (2001) Drug Information J. , vol.35 , pp. 337-346
- Reichert, J.M.¹

14
- 0034283885
- New biopharmaceuticals in the USA: Trends in development and marketing approvals 1995-1999
- (2000) Nat. Biotechnol. , vol.18 , pp. 364-369
- Reichert, J.M.¹

15
- 0035095214
- Fast track product designation under the Food and Drug Administration Modernization Act: The industry experience
- (2001) Drug Information J. , vol.35 , pp. 71-83
- Milne, C.-P.¹ Bergman, E.²

16
- 0036376717
- The single controlled trial: Industry survey indicates that implementation is still a work in progress
- (2002) Drug Information J. , vol.36 , pp. 291-301
- Milne, C.-P.¹

17
- 0003661227
- PAREXEL International Corp., Boston, MA
- (2001) New Drug Development: a Regulatory Overview , pp. 408
- Mathieu, M.¹

18
- 0003995253
- PAREXEL International Corp., Boston, MA
- (2002) PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2001 , pp. 256-257
- Mathieu, M.¹

19
- 0001809038
- Pharma 2005: An industrial revolution in R&D
- January
- (2000) Pharmaceutical Exec. , pp. 74-84
- Arlington, S.¹

20
- 2142784608
- Growing up backwards
- (2002) Biocentury: The Bernstein Report on Business , vol.10 , Issue.20
- Haan, K.¹

21
- 2142682232
- Biotechnology has become vital to orphan product development
- (2002) Tufts Center for the Study of Drug Development Impact Report , vol.4 , Issue.3
- Kaitin, K.I.¹

22
- 2142739215
- Pharma: Can the middle hold?
- (2001) McKinsey Quarterly , vol.1 , pp. 117-125
- Bastianelli, E.¹

23
- 0033763969
- The distribution of sales revenues from pharmaceutical innovation
- (2000) PharmacoEconomics Supp. , vol.1 , pp. 21-32
- Grabowski, H.G.¹ Vernon, J.²

24
- 2142789664
- FDA office of orphan products development FY 2001 accomplishments
- March 14
- (2002) FDA Talk Paper

25
- 2142679725
- FDA orphan drug grants would double to $25 mil. in Kennedy/Hatch Bill
- October 22
- (2001) The Pink Sheet , pp. 9

26
- 26144463252
- Report # OEI-09-00-00380, May
- (2001) The orphan drug act: implementation and impact

27
- 4243295625
- The plagues of poverty
- March 19
- (2002) New York Times

28
- 0009492919
- Health spending projections for 2001-2011: The latest outlook
- March/April
- (2002) Health Affairs , pp. 207-216
- Heffler, S.¹

29
- 0034625766
- Disease group invests in do-it-yourself drugs
- (2000) Science , vol.288 , pp. 1715-1717
- Marshall, E.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.